FORT MYERS, Fla. - Harris Pharmaceutical is focused on doing one thing and doing it well: becoming a preferred provider of generic products with dermatological indications.
To that end, Harris has launched two new products: Metronidazole Topical Cream 0.75% and Hydroxyzine HCl Tablets in 10-, 25- and 50-mg strengths.
Citing figures from IMS Health, Harris says Metronidazole Topical Cream 0.75% had total sales of about $12 million for the year ended August 2008. Sales of Hydroxyzine HCl Tablets exceeded $70 million for the same period.
The addition of these two products has increased the total number of new products launched in 2008 to five, with a total of seven new products since late 2007.
The line now comprises several first-time generics, including Terbinafine HCl Tablets and Ciclopirox Nail Lacquer as well as Mometasone and Benzoyl Peroxide products.
Harris Pharmaceutical was founded in 2002 with a mission to provide dermatologists and their patients with safe, effective and affordable generics that offer the same therapeutic benefits as branded products but at a fraction of the cost.
Harris' initial years were spent focusing on its primary strategy: to develop, manufacture and commercialize its own abbreviated new drug applications (ANDAs). Its first ANDA, Terbinafine HCl Tablets, was launched in July 2007, an din order to offer patients and customers a broad dermatological product portfolio, Harris has been acquiring and licensing additional products in its niche.
Through these collaborations Harris has quickly increased its product line over the past 18 months to now represent a variety of dosage forms, including oral solids, topical creams, ointments, liquids, and washes, all targeted toward the dermatology market.
Besides the multiple new products already launched, Harris has further ANDAs pending Food and Drug Administration approval, with additional products in development.
